Last Thursday, Shkreli was arrested on charges of securities fraud, to which he pleaded not guilty.
KaloBios said in its release that Tony Chase, a member of the board, has resigned as well.
KaloBios did not name an interim CEO.
Shkreli joined KaloBios in November after acquiring 70 percent of the company. On the day of his arrest, the stock dropped 50 percent before being halted.
Earlier this month, Shkreli and KaloBios acquired a drug to treat Chagas disease, a parasitic infection that affects about 300,000 people in the US. He planned to seek FDA approval for the drug, benznidazole, which he would then price anywhere from $60,000 to $100,000 per course of treatment. The CDC currently gives benznidazole away for free to people in the US with acute infection.
UC Davis and the Moffitt Cancer Center in Florida, which were running a clinical trial for a KaloBios drug to treat a form of leukemia, have suspended the trials “pending further analysis,” according to Bloomberg.
This article was originally published on Business Insider. Copyright 2015.
